| 货号 | AF2017-SP |
| 别名 | CD85 antigen-like family member J; CD85j antigen; CD85j; Ig-like transcript 2; ILT2; ILT-2; ILT2FLJ37515; Immunoglobulin-like transcript 2; leukocyte Ig-like receptor-1; Leukocyte immunoglobulin-like receptor 1; leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform; leukocyte immunoglobulin-like receptor subfamily B member 1; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains); LIR1; LIR1LIR-1MIR-7CD85MIR7CD85 antigen; member 1; MIR7; Monocyte/macrophage immunoglobulin-like receptor 7 | 全称 | Leukocyte Immunoglobulin-like Receptor, Subfamily A (with TM domain), Member 1 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) Flow Cytometry(2.5 µg/106cells) |
| 目标/特异性 | Detects human LILRB1/CD85j/ILT2 in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant human (rh) ILT4 is observed and 15% cross-reactivity with rhILT5 is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Flow Cytometry: 2.5 µg/106cells Neutralization: Measured by its ability to neutralize LILRB1/CD85j/ILT2-mediated adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line. Cosman, D. et al. (1997) Immunity 7:273. The Neutralization Dose (ND50) is typically 0.3-1.0 µg/mL in the presence of 5 µg/mL Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 10859 (Human) |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human LILRB1/CD85j/ILT2 Gly24-His458 Accession # Q8NHL6 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | The immunoglobulin-like transcript (ILT) family of activating and inhibitory type immunoreceptors are expressed on many leukocyte subsets and function in the regulation of immune responses (1‑3). This family was also named leukocyte Ig-like receptors (LIR) and monocyte/macrophage Ig-like receptors (MIR). ILTs share significant homology with killer cell Ig-like receptors (KIR). The ILT genes are located on human chromosome 19q13.4 in the leukocyte receptor complex, which also include the genes encoding KIRs (4). With the exception of ILT-6, which is a soluble molecule, all ILT family members are type I transmembrane proteins having two or four extracellular Ig-like domains (2, 3). One subset of the ILT receptors (referred to as subfamily B of the LIRs) has long cytoplasmic tails containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events by recruiting SH2-containing protein tyrosine phosphatase-1. Another subset of the ILT receptors (referred to as subfamily A of the LIRs) contains activating receptors with short cytoplasmic regions that lack signal transduction motifs. These receptors contain a basic arginine residue within their transmembrane domains, which allows association with Fc R gamma, an immunoreceptor tyrosine-based activation motif (ITAM)-bearing signal adapter protein (1‑3). ILT2, also known as LIR1, MIR7, and CD85j, is expressed on most monocytes, dendritic cells, and mature B cells (1‑3). It is also expressed on small percentages of T cells and NK cells. ILT2 has four extracellular Ig-like domains and three cytoplasmic ITIMs. It functions as an inhibitory receptor that prevents cellular activation. ILT2 has been shown to bind classical (HLA-A and -B) and nonclassical (HLA-G1, -E and -F) MHC class I molecules (MHCI) (1‑3). ILT2 also binds with high affinity to an MHC class I homologue from human cytomegalovirus (3). Ligation of ILT2 by MHC class I may function to poise cellular activation thresholds and inhibit various leukocyte effector mechanisms that are regulated by MHC class I molecules on target cells. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Cell Adhesion Mediated by LILRB1/CD85j/ILT2 and Neutralization by Human LILRB1/CD85j/ILT2 Antibody. Recombinant Human LILRB1/CD85j/ILT2j Fc Chimera (Catalog # 2017-T2), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera (5 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human LILRB1/CD85j/ILT2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2017). The ND50 is typically 0.3-1.0 µg/mL. |
